NRX-101
Suicidal Bipolar Depression (Acute/Sub-Acute Suicidal Ideation & Behavior)
Phase 2Active; Breakthrough Therapy & Fast Track Designation; Positive Phase 2 data
Key Facts
Indication
Suicidal Bipolar Depression (Acute/Sub-Acute Suicidal Ideation & Behavior)
Phase
Phase 2
Status
Active; Breakthrough Therapy & Fast Track Designation; Positive Phase 2 data
Company
About NRx Pharmaceuticals
NRx Pharmaceuticals is a public company (Nasdaq: NRXP) focused on developing life-saving treatments for suicidal depression, bipolar depression, and PTSD. Its core technology targets the brain's NMDA and 5-HT2A receptors with a non-hallucinogenic, non-addictive approach. Key achievements include positive Phase 2 data for NRX-101, FDA designations for its lead program, and the submission of an ANDA for NRX-100, positioning it as a leader in neuroplastic therapies for severe mental health crises.
View full company profile